Procurement of the drug Tenecteplase

This tender for Tenecteplasum procurement presents a strong opportunity for established pharmaceutical suppliers with robust supply chains and a clear understanding of regulatory compliance. The absence of specified evaluation criteria suggests a primary focus on meeting all mandatory requirements and offering competitive pricing.

Reliable and Compliant Supply of Essential Medication

Cost-Effective Solution Meeting All Technical Demands

Ensure 100% accuracy and completeness in all mandatory forms and documentation. Double-check all technical specifications against the product offering. Verify all financial data for accuracy and competitiveness.

Develop a pricing strategy that is highly competitive while ensuring profitability. Analyze market rates for Tenecteplasum and consider the estimated value of 1.0 (likely a placeholder or unit value, requiring careful interpretation).

Thoroughly review and complete all mandatory forms, including 'Pielikums_1_pieteikums_RAKUS_2026_44' and 'Pielikums_2_Apliecinājums_par_neatkarīgi_izstrādātu_piedāvājumu_RAKUS_2026_44', ensuring no errors or omissions. Pay close attention to the 'Iepirkuma priekšmeta prasības, 1.versija' for exclusion conditions and proposal requirements.

Ensure the proposed Tenecteplasum product precisely matches all parameters detailed in 'Pielikums_3_Tehniskā specifikācija_RAKUS_2026_44', including active substance, dosage, and quantity. Any deviation must be explicitly addressed and justified if permitted.

Develop a highly competitive pricing strategy. Given the lack of explicit evaluation criteria, price will likely be a significant, if not the sole, deciding factor after mandatory compliance. Analyze market rates and the estimated value carefully.

While not explicitly scored, subtly emphasize the robustness and reliability of your supply chain for Tenecteplasum. This can be framed as an assurance of consistent availability, a critical factor for a hospital.

Carefully review 'Pielikums_4.1._Vispārīgās_vienošanās_projekts_RAKUS_2026_44' and 'Pielikums_4.2._Līguma projekts_RAKUS_2026_44' to identify any potential contractual risks or onerous clauses. Seek legal counsel if necessary.

Seek clarification from the contracting authority regarding the 'Estimated Value: 1.0'. This is highly unusual and could represent a unit value, a placeholder, or a significant misunderstanding. Clarification is crucial for accurate pricing.

This tender for medication procurement is generally well-structured with clear documentation and a reasonable process. However, concerns exist regarding the extremely low estimated value and potential access restrictions to certain documents, impacting fairness and practicality.

The tender adheres to open procedure, specifies a CPV code, and has a reasonable timeline. No disputes are noted. The estimated value of 1.00 EUR is highly unusual and could indicate a procedural issue or a placeholder, potentially affecting the legal interpretation of the procurement's scale.

The tender title, description, and listed documents provide a clear understanding of the procurement's objective. Technical specifications and contract drafts are referenced, contributing to clarity. However, the absence of explicit evaluation criteria is a notable omission.

Most basic information is present, including the organization, reference, type, procedure, and timeline. Key documents like technical specifications and contract drafts are listed. The estimated value and contract duration are specified. However, the extremely low estimated value raises questions about completeness.

The tender is an open competition, and essential documents like technical specifications and contract drafts are provided. The use of e-procurement is a positive aspect. However, the extremely low estimated value could be perceived as a way to limit competition or is a significant oversight. The AI flags 'Restricted document access' which, if true, would severely impact fairness.

The tender utilizes e-procurement, which is practical. However, the extremely low estimated value of 1.00 EUR makes the financial aspects impractical and potentially misleading. The contract duration is specified. The AI flags 'No e-submission', which contradicts the 'E-Procurement' characteristic and needs clarification.

Key fields such as title, reference, organization, and deadlines are populated. The dates provided (Reveal, Submission, Opening) are logically ordered. No disputes or suspensions are noted. The estimated value of 1.00 EUR is consistent with itself but highly inconsistent with a typical medication procurement.

There is no explicit mention of green procurement, social aspects, or innovation within the provided tender details. The tender is not indicated as EU funded.